Edimburgh BPS/SFP meeting – September 97

0
Rate this post

bps-6909729BRITISH PHARMACOLOGICAL SOCIETY Autumn Meeting 1-4 September 1997 University of Edinburgh Joint meeting with the Société Française de Pharmacologie

Deadline for abstracts: 12th-19th June 1997

EDHF: MYTH OR CHEMICAL ENTITY?*

  • Introduction: The other EDRF(s)
 P.M. Vanhoutte
I.R.I.S., Courbevoie, France
M. Félétou
I.d.R.S. Suresnes, France
  • EDHF and Vascular Smooth Muscle
 A.H. Weston
University of Manchester, UK
R. Cohen
Boston University Medical Center, USA
  • Is the answer a P450 metabolite?
 R. Busse
J.W.G.-Universität, Frankfurt/Main, Germany
  • Is the answer a cannabinoid?
 D.A. Kendall,
University of Nottingham, UK
  • Can it be all of the above?
 J.V. Mombouli
Baylor College of Medicine, Houston, USA
  • Conclusion: Myth or reality?
 P.M. Vanhoutte
I.R.I.S., Courbevoie France

*Sponsored by I.R.I.S.

HANS KOSTERLITZ MEMORIAL SYMPOSIUM

Hans Kosterlitz, who died last year, made an outstanding contribution to pharmacology, particularly in the field of enkephalins and endorphins. As a tribute to Professor Kosterlitz, some of his former students and colleagues have been invited to talk about their current research. They are:

Graeme Henderson University of Bristol, UK
John Hughes, FRS University of Cambridge, UK
Sandy McKnight University of Cambridge, UK
Frances Leslie University of California, Irvine, USA
R. Alan North, FRS Geneva Biomedical Research Institute of GlaxoWellcome, Switzerland

THE PHARMACOLOGY & CLINICAL PHARMACOLOGY OF ENDOTHELIN

  • The Molecular Biology of endothelin-converting enzyme
 O. Valdenaire
Hoffmann La Roche, Basel, Switzerland
  • Structure and localisation of endothelin-converting enzyme
 A.J. Turner
University of Leeds, UK
  • Biochemistry of endothelin-converting enzyme
 R. Corder
William Harvey Research Institute, London, UK
  • Pharmacology of endothelin receptors
 A.P. Davenport
University of Cambridge, UK
  • Clinical Pharmacology of endothelin
 D.J. Webb
University of Edinburgh, UK
  • Endothelin antagonists in pulmonary hypertension: clinicale and xperimental studies
 S. Adnot
Faculté de Médecine, Hôpital Henri Mondor, Paris, France
  • Endothelin in experimental models of heart failure
 C. Thuillez
Universite de Rouen, France
  • Clinical Pharmacology of endothelin receptor antagonists in heart failure
 J.J.V. McMurray
University of Glasgow, UK

THERAPEUTIC TARGETS IN APOPTOSIS RESEARCH

  • Introduction to apoptosis
 A.H. Wyllie
University of Edinburgh, UK
  • Cytokines & the control of apoptosis in the human atherosclerotic plaque
 A. Tedgui
INSERM U141, Hôpital Lariboisière, Paris, France
  • Molecular basis of apoptosis in Parkinson’s disease: a pharmacological approach
 E. Hirsch
INSERM U289, Hôpital de la Salpétrière, Paris, France
  • Apoptosis and programmed cell-death: in cerebral ischaemia
 C. Charriaut-Marlangue
INSERM U29, Hôpital Port Royal, Paris, France
  • Glucocorticoid induced apoptosis: transcriptional mechanisms
 M. Pallardy
INSERM U461, Faculté de Pharmacie, Chateray, France
  • CD95 (APO-1/Fas)-mediated apoptosis and disease
 P.H. Krammer
German Cancer Research Center, Heidelberg, Germany
  • Ceramide/stress kinase-mediated apoptosis
 R. Kolesnick
Sloan-Kettering Cancer Center, New York, USA
  • Endogenous regulators of apoptosis
 R. Brown
GlaxoWellcome, Stevenage, UK
  • Effector enzymes in apoptosis
 D.W. Nicholson
Merck Frost Centre for Therapeutics Research, Quebec, Canada
C. Haslett
University of Edinburgh, UK

Chairmen: H.J. Olverman, Edinburgh & M. Hamon, Paris

  • Constitutive and inducible knockout of the 5HT1A receptor: behavioural consequences
 S. Ramboz
Columbia University New York, USA
  • Differential adaptive regulations of pre- versus post-synaptic 5-HT1A receptors
 L. Lanfumey
INSERM U288, Paris, France
  • Oestrogen control of 5-HT neurotransmission
 G. Fink
MRC Brain Metabolism Unit, University of Edinburgh, UK
  • Neuropharmacology of 5-HT Modulin
 G. Fillion
Institut Pasteur, Paris, France
  • Multireceptorial control of 5-HT, dopamine and noradrenaline release in frontal cortex: strategies for improved antidepressant drugs.
 M. Millan
Centre de Recherche Servier, Croissy, France
  • Development of radioligands for imaging 5-HT1A receptors with PET
 V.W. Pike
MRC Clinical Sciences Centre, Hammersmith Hospital, London, UK
  • 5-HT transporter gene polymorphism and depression
 A.D. Ogilvie
University of Cambridge, UK
J.S. Kelly
University of Edinburgh, UK

* Sponsored by the Serotonin Club

SPONSORED LECTURES

SmithKline Beecham Lecture

Professor Patrick J. Vallance, Centre for Clinical Pharmacology, Cruciform Project, University College, London

“Exploring the L-arginine: nitric oxide pathway in the human cardiovascular system”.

ASCEPT* Lecture

* The Australian Society of Clinical and Experimental Pharmacologists and Toxicologists

Professor Richard O. Day,

Clinical Pharmacology/Toxicology, St Vincent’s Hospital, Sydney, Australia

“The clinical pharmacology of anti-inflammatory and anti-rheumatic drugs”.

The meeting will be followed, on 5-6 September, by an international meeting to commemorate the work of James Young Simpson and the sesquicentenary of chloroform.